A subpopulation of B− cells, namely B1 cells (MHCII+, CD19+, CD11b++), which are important for anti-tumor immune response [41], was significantly increased in the NSC243928 treated tumor isografts from the E0771 model (Figure 5E). The gene discussed is CD19; the disease is neoplasm.